Reference : Grundlagen und Stellenwert der COMT- und MAO-B-Inhibitoren in der Therapie des idiopa...
Scientific journals : Article
Human health sciences : Neurology
Systems Biomedicine
http://hdl.handle.net/10993/43841
Grundlagen und Stellenwert der COMT- und MAO-B-Inhibitoren in der Therapie des idiopathischen Parkinson-Syndroms.
German
[en] The role of inhibitors of COMT and MAO-B in the therapy of Parkinson's disease
Woitalla, Dirk [Neurologische Klinik, Kathol. Kliniken der Ruhrhalbinsel.]
Krüger, Rejko mailto [University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit]
Lorenzl, Stefan [Paracelsus Medizinische Privatuniversität, Institut für Pflegewissenschaft und -praxis, Salzburg.]
Müller, Thomas [lexianer St. Joseph Berlin-Weißensee GmbH, Berlin.]
Oelwein, Guenther [Neurologische Praxis, Gera.]
Storch, Alexander [Klinik und Poliklinik für Neurologie, Universität Rostock, und Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) Rostock/Greifswald, Rostock.]
Wolz, Martin [Klinik und Poliklinik für Neurologie, Elblandkliniken Meissen-Radebeul.]
Wüllner, Ullrich [Klinik und Poliklinik für Neurologie, Universitätsklinikum Bonn & Deutsches Zentrum für neurodegenerative Erkrankungen (DZNE Bonn).]
28-Mar-2020
Fortschritte der Neurologie-Psychiatrie
Yes (verified by ORBilu)
International
0720-4299
1439-3522
Germany
[en] Parkinson’s disease ; MAO-B inhibitors ; COMT inhibitors
[en] Inhibitors of COMT and MAO-B are well established in the pharmacotherapy of Parkinson's disease (PD). MAO-B inhibitors are used as monotherapy as well as in combination with levodopa, whereas COMT inhibitors exert their effects only in conjungtion with levodopa. Both classes of compounds prolong the response duration of levodopa and optimise its clinical benefit. As a result, the ON-times are prolonged significantly. In the past, MAO-B inhibitors were also adminstered for neuroprotection; however, despite convincing scientific reasoning in support of neuroprotective effects, these could not be substantiated in clinical studies performed so far.
http://hdl.handle.net/10993/43841
10.1055/a-1149-9308
https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-1149-9308
not OA
© Georg Thieme Verlag KG Stuttgart · New York.

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Limited access
FDNP-0394-02-2020-FW.R2 Parkinson_Approval-PDF_COMT.pdfPublisher postprint817.95 kBRequest a copy

Bookmark and Share SFX Query

All documents in ORBilu are protected by a user license.